Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Adagene Inc (ADAG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ADAG (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.89
1 Year Target Price $9.89
| 0 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.12% | Avg. Invested days 20 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 94.69M USD | Price to earnings Ratio - | 1Y Target Price 9.89 |
Price to earnings Ratio - | 1Y Target Price 9.89 | ||
Volume (30-day avg) 3 | Beta 0.74 | 52 Weeks Range 1.32 - 3.58 | Updated Date 08/15/2025 |
52 Weeks Range 1.32 - 3.58 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.64 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.33 | Actual -0.29 |
Profitability
Profit Margin - | Operating Margin (TTM) -32283.6% |
Management Effectiveness
Return on Assets (TTM) -24.89% | Return on Equity (TTM) -63.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 38711981 | Price to Sales(TTM) 917.51 |
Enterprise Value 38711981 | Price to Sales(TTM) 917.51 | ||
Enterprise Value to Revenue 375.1 | Enterprise Value to EBITDA 1.12 | Shares Outstanding 47109600 | Shares Floating 12804388 |
Shares Outstanding 47109600 | Shares Floating 12804388 | ||
Percent Insiders 4.7 | Percent Institutions 33.14 |
Upturn AI SWOT
Adagene Inc
Company Overview
History and Background
Adagene Inc. is a clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Founded to address significant unmet medical needs, Adagene utilizes its proprietary D-Body and SAFEbody platforms to generate differentiated antibody candidates with improved safety and efficacy profiles. The company is headquartered in San Diego, California, and Suzhou, China.
Core Business Areas
- Antibody Discovery and Engineering: Adagene's core expertise lies in discovering and engineering novel antibody-based therapies using its proprietary D-Body and SAFEbody platforms. This includes generating antibodies with optimized binding affinity, specificity, and safety profiles.
- Clinical Development: Adagene is actively involved in clinical development, conducting Phase 1 and Phase 2 trials to evaluate the safety and efficacy of its antibody candidates in various cancer indications.
- Partnerships and Licensing: Adagene seeks strategic partnerships and licensing agreements to expand the reach of its technology and accelerate the development of its antibody programs.
Leadership and Structure
Adagene Inc. is led by a management team with experience in antibody engineering, clinical development, and business strategy. The company operates with a functional organizational structure, with distinct departments for research and development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- ADG106 (anti-CD137 agonistic antibody): An agonistic anti-CD137 antibody designed to selectively activate CD137-expressing immune cells in the tumor microenvironment. It is in clinical development for advanced solid tumors. Competitors include Bristol Myers Squibb (Utomilumab), and Roche (RG7826). Market share data or revenue for individual products is not publicly available.
- ADG126 (anti-CTLA-4 SAFEbody): A SAFEbody anti-CTLA-4 antibody engineered to minimize systemic toxicity and enhance anti-tumor activity. It is in clinical development for advanced solid tumors. Competitors include Ipilimumab (Yervoy) by Bristol Myers Squibb, and Tremelimumab. Market share data or revenue for individual products is not publicly available.
- ADG116 (anti-PD-L1):: A SAFEbody anti-PD-L1 antibody engineered to minimize systemic toxicity and enhance anti-tumor activity. Competitors include Atezolizumab (Tecentriq) by Roche, Pembrolizumab (Keytruda) by Merck, and Nivolumab (Opdivo) by Bristol Myers Squibb. Market share data or revenue for individual products is not publicly available.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense competition, rapid technological advancements, and high regulatory hurdles. The cancer immunotherapy market is experiencing significant growth driven by the increasing prevalence of cancer and the development of novel therapies.
Positioning
Adagene is positioned as an innovative biotechnology company focused on developing next-generation antibody-based cancer immunotherapies. Its D-Body and SAFEbody platforms provide a competitive advantage by enabling the generation of differentiated antibodies with improved safety and efficacy profiles.
Total Addressable Market (TAM)
The global cancer immunotherapy market is projected to reach hundreds of billions of dollars in the coming years. Adagene is targeting specific segments within this market, including solid tumors, with the aim of capturing a significant share. Specific TAM figures and Adagene's positioning require detailed market analysis not readily available.
Upturn SWOT Analysis
Strengths
- Proprietary D-Body and SAFEbody platforms
- Strong scientific expertise in antibody engineering
- Promising preclinical and clinical data
- Experienced management team
- Dual headquarters in the US and China
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Early-stage clinical development programs
- Reliance on partnerships and licensing agreements
- Potential for clinical trial failures
- Dependence on key personnel
Opportunities
- Expanding the pipeline with new antibody candidates
- Advancing clinical programs into later stages of development
- Securing strategic partnerships with pharmaceutical companies
- Expanding into new geographic markets
- Acquiring complementary technologies or assets
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Clinical trial failures
- Intellectual property disputes
- Economic downturns
Competitors and Market Share
Key Competitors
- BMY
- MRK
- RHHBY
Competitive Landscape
Adagene's advantage lies in its novel antibody engineering platforms. However, larger pharmaceutical companies possess greater resources for development and commercialization.
Growth Trajectory and Initiatives
Historical Growth: Adagene's historical growth is reflected in its pipeline advancement and strategic partnerships. Specific growth metrics require access to historical financial data.
Future Projections: Future growth projections depend on the success of its clinical programs and its ability to secure partnerships. Analyst estimates are not readily available without access to financial data providers.
Recent Initiatives: Recent initiatives include progressing clinical trials for ADG106 and ADG126, and pursuing strategic collaborations for further development.
Summary
Adagene is a clinical-stage biotech company with promising antibody-based cancer immunotherapy platforms. The company faces challenges with limited financial resources and competition from larger firms. Its strengths are its proprietary technology and pipeline. Opportunities lie in pipeline advancement and partnerships, but threats include clinical trial failures and competition. Overall, Adagene's innovative technology provides a potential advantage in the market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Press Releases
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share estimates are approximate and based on available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adagene Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-02-09 | Co- Founder, Chairman, CEO and President of R&D Dr. Peter P. Luo Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 138 | Website https://www.adagene.com |
Full time employees 138 | Website https://www.adagene.com | ||
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.